Cargando…

Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review

Tuberculosis (TB), considered an ancient disease, is still killing one person every 21 seconds. Diagnosis of Mycobacterium tuberculosis (M.tb) still has many challenges, especially in low and middle-income countries with high burden disease rates. Over the last two decades, the amount of drug-resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Yusoof, Kizil A., García, Juan Ignacio, Schami, Alyssa, Garcia-Vilanova, Andreu, Kelley, Holden V., Wang, Shu-Hua, Rendon, Adrian, Restrepo, Blanca I., Yotebieng, Marcel, Torrelles, Jordi B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301132/
https://www.ncbi.nlm.nih.gov/pubmed/35874762
http://dx.doi.org/10.3389/fimmu.2022.870768
_version_ 1784751363204317184
author Yusoof, Kizil A.
García, Juan Ignacio
Schami, Alyssa
Garcia-Vilanova, Andreu
Kelley, Holden V.
Wang, Shu-Hua
Rendon, Adrian
Restrepo, Blanca I.
Yotebieng, Marcel
Torrelles, Jordi B.
author_facet Yusoof, Kizil A.
García, Juan Ignacio
Schami, Alyssa
Garcia-Vilanova, Andreu
Kelley, Holden V.
Wang, Shu-Hua
Rendon, Adrian
Restrepo, Blanca I.
Yotebieng, Marcel
Torrelles, Jordi B.
author_sort Yusoof, Kizil A.
collection PubMed
description Tuberculosis (TB), considered an ancient disease, is still killing one person every 21 seconds. Diagnosis of Mycobacterium tuberculosis (M.tb) still has many challenges, especially in low and middle-income countries with high burden disease rates. Over the last two decades, the amount of drug-resistant (DR)-TB cases has been increasing, from mono-resistant (mainly for isoniazid or rifampicin resistance) to extremely drug resistant TB. DR-TB is problematic to diagnose and treat, and thus, needs more resources to manage it. Together with+ TB clinical symptoms, phenotypic and genotypic diagnosis of TB includes a series of tests that can be used on different specimens to determine if a person has TB, as well as if the M.tb strain+ causing the disease is drug susceptible or resistant. Here, we review and discuss advantages and disadvantages of phenotypic vs. genotypic drug susceptibility testing for DR-TB, advances in TB immunodiagnostics, and propose a call to improve deployable and low-cost TB diagnostic tests to control the DR-TB burden, especially in light of the increase of the global burden of bacterial antimicrobial resistance, and the potentially long term impact of the coronavirus disease 2019 (COVID-19) disruption on TB programs.
format Online
Article
Text
id pubmed-9301132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93011322022-07-22 Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review Yusoof, Kizil A. García, Juan Ignacio Schami, Alyssa Garcia-Vilanova, Andreu Kelley, Holden V. Wang, Shu-Hua Rendon, Adrian Restrepo, Blanca I. Yotebieng, Marcel Torrelles, Jordi B. Front Immunol Immunology Tuberculosis (TB), considered an ancient disease, is still killing one person every 21 seconds. Diagnosis of Mycobacterium tuberculosis (M.tb) still has many challenges, especially in low and middle-income countries with high burden disease rates. Over the last two decades, the amount of drug-resistant (DR)-TB cases has been increasing, from mono-resistant (mainly for isoniazid or rifampicin resistance) to extremely drug resistant TB. DR-TB is problematic to diagnose and treat, and thus, needs more resources to manage it. Together with+ TB clinical symptoms, phenotypic and genotypic diagnosis of TB includes a series of tests that can be used on different specimens to determine if a person has TB, as well as if the M.tb strain+ causing the disease is drug susceptible or resistant. Here, we review and discuss advantages and disadvantages of phenotypic vs. genotypic drug susceptibility testing for DR-TB, advances in TB immunodiagnostics, and propose a call to improve deployable and low-cost TB diagnostic tests to control the DR-TB burden, especially in light of the increase of the global burden of bacterial antimicrobial resistance, and the potentially long term impact of the coronavirus disease 2019 (COVID-19) disruption on TB programs. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9301132/ /pubmed/35874762 http://dx.doi.org/10.3389/fimmu.2022.870768 Text en Copyright © 2022 Yusoof, García, Schami, Garcia-Vilanova, Kelley, Wang, Rendon, Restrepo, Yotebieng and Torrelles https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yusoof, Kizil A.
García, Juan Ignacio
Schami, Alyssa
Garcia-Vilanova, Andreu
Kelley, Holden V.
Wang, Shu-Hua
Rendon, Adrian
Restrepo, Blanca I.
Yotebieng, Marcel
Torrelles, Jordi B.
Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title_full Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title_fullStr Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title_full_unstemmed Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title_short Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review
title_sort tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301132/
https://www.ncbi.nlm.nih.gov/pubmed/35874762
http://dx.doi.org/10.3389/fimmu.2022.870768
work_keys_str_mv AT yusoofkizila tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT garciajuanignacio tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT schamialyssa tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT garciavilanovaandreu tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT kelleyholdenv tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT wangshuhua tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT rendonadrian tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT restrepoblancai tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT yotebiengmarcel tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview
AT torrellesjordib tuberculosisphenotypicandgenotypicdrugsusceptibilitytestingandimmunodiagnosticsareview